BioInvent International
16,76 SEK +1,21 %1 investor følger denne virksomhed
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Omsætning
326,13 mio.
EBIT %
-15,61 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
BINV
Daglig lav / høj pris
16,56 / 16,92
SEK
Markedsværdi
1,1 mia. SEK
Aktieomsætning
358,76 t SEK
Volumen
21 t
Seneste videoer
Finanskalender
Delårsrapport
26.10.2023
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Redmile Group, LLC | 15,4 % | 15,4 % |
| Van Herk Investments | 10,1 % | 10,1 % |
Premium
Not activated
This content is for our Premium customers only.
Viser Alle indholdstyper
